Interview with Dr Richard W Barker, Director General, Association of the British…
Taking a look at a key achievement of the ABPI in recent years, we recognize the role you played in negotiating the revised PPRS that was put in place last…
Address: 1 Royal College St ,London, Greater London NW1 0SB, UK
Tel: +44(0) 20 7691 4906
Web: http://www.xeneticbio.com/
Xenetic is a leading UK based biopharmaceutical company providing leading edge expertise in the development of a whole new generation of drugs and vaccines.
Working with some of the largest pharmaceutical organisations in the world, Xenetic provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas.
We are also actively developing our own pipeline of next generation biotherapeutics based on our proprietary PolyXen andImuXen platform technologies.
Xenetic’s biopharmaceutical pipeline contains a range of product candidates which are currently under development either in-house or with biotechnology and pharmaceutical partners. The products in Xenetic’s pipeline have a multi-billion dollar market potential.
Pipeline products are based on Xenetic’s proprietary drug and vaccine delivery technologies and have been developed to offer improved performance and delivery characteristics. Xenetic’s unique delivery technologies are also able to create new high-value, differentiated proprietary products from off-patent actives.
Xenetic has established a range of partnerships with major US, European, Russian and Asian biotechnology and pharmaceutical companies to develop new protein therapeutics and vaccines. Click here to learn more about the work we do with our partners.
Taking a look at a key achievement of the ABPI in recent years, we recognize the role you played in negotiating the revised PPRS that was put in place last…
It are exciting times for the UK, with the public healthcare system undergoing so many changes. The Office of Life Sciences (OLS) and the Therapeutic Capability Clusters are just some…
As part of a panel discussion with Claudia Hammond of the BBC last year, you commented on the fairly poor relationship between the NHS and industry, and the need to…
Together with Germany, the UK the highest generic penetration rate in Europe. Since you have been with the association since 1995 and obviously saw the great emergence of the generic…
Thank you for having us today! You have been chief executive of the Association since 1990 and obviously observed the evolution of the OTC market from close by. From your…
Given the heated debate over NHS reform and the new revised bill proposed by the government, what are you current priorities as President of the ABPI and how have these…
See our Cookie Privacy Policy Here